Develops investigational oral antiviral therapies for influenza and COVID, and cancer drug candidates for people with solid tumors and blood cancers.
10-K for FY2024, filed Apr 15, 2026Traws Pharma, Inc. (“Traws,” “we,” or the “Company”) is a clinical stage biopharmaceutical company dedicated to developing novel therapies…View ↗
On April 1, 2024, the Company (then known as Onconova Therapeutics, Inc.) consummated a merger (the “Merger”) with Trawsfynydd…View ↗
Tivoxavir marboxil, is a small molecule cap-dependent endonuclease inhibitor. Cap-dependent endonuclease (“CEN”) is an enzyme that is…View ↗
Ratutrelvir — Small Molecule - 3CL Protease InhibitorView ↗
Pursuant to a license agreement with Temple University, dated January 1, 1999, as amended March 21, 2013 (the “Temple Licensing…View ↗
The company earns money by licensing rights to product candidates; partners can pay upfront, when development or regulatory milestones are met, and royalties on sales of licensed products.
10-K for FY2024, filed Apr 15, 2026The Company enters into licensing and collaboration agreements, under which it licenses certain of its product candidates’ rights to third…View ↗
Licensing of Intellectual Property: If the license to the Company’s intellectual property is determined to be distinct from the other…View ↗
Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the…View ↗
Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the…View ↗
$2.8M
10-K for FY2024, filed Apr 15, 2026
$2.8M ↗
Other companies license rights to product candidates; if products reach market, Traws may use licensing or co-promotion partners for marketing and distribution.
10-K for FY2024, filed Apr 15, 2026
Yes. Its net income in FY2025 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$20.8M.
10-Q for Q2 FY2026, filed Aug 14, 2026
−$3.1MView ↗
Growing. Revenue grew 12.3x in 4 years, from $226K in FY2021 to $2.8M in FY2025, about 87% a year.
Added respiratory-virus programs
The older report describes a cancer-focused pipeline with narazaciclib and rigosertib. The latest report adds antiviral candidates for influenza and COVID while retaining those cancer programs.
10-K for FY2021, filed Mar 21, 2022 10-K for FY2024, filed Apr 15, 2026Onconova Therapeutics, Inc., sometimes referred to as “we” or the “Company,” is a clinical-stage biopharmaceutical company focused on…View ↗
Competes with Gilead, Glaxo SmithKline, BioCryst, Roche, Cidara, Eradivir, Pfizer, Merck, Ridgeback, Novartis, and Eli Lilly
10-K for FY2024, filed Apr 15, 2026There are currently various drugs approved for the treatment of influenza, including without limitation the neuraminidase inhibitors…View ↗
Loading...